Activation status of astrocytes drives the MS/NMOSD therapeutic paradox: Insights from IFNAR1 signaling
Cell Reports · 2026-02 · 45 (2) · 116913
DOI: 10.1016/j.celrep.2025.116913 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-02. Verfasst von Luhang Dai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Medicinal Resources and Natural Pharmaceutical Chemistry, Ministry of Education, College of Life Sciences, Shaanxi Normal Universi…. Hauptthemen laut MEDLINE: Astrocytes, Receptor, Interferon alpha-beta, Signal Transduction, Neuromyelitis Optica. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shaanxi Province Natural Science Foundation, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory disease of the central nervous system (CNS) that, despite overlapping phenotypic features with multiple sclerosis (MS), manifests with more severe clinical outcomes. The defining pathogenic driver of NMOSD is the aquaporin-4 (AQP4) autoantibody, which induces astrocytic injury via complement-dependent cytotoxicity (CDC). MS is predominantly managed with disease-modifying therapies (DMTs) such as interferon-beta (IFN-β) to reduce relapse rates. However, these therapies are often ineffective or even detrimental in NMOSD. Our findings demonstrate that while IFN-β mitigates experimental autoimmune encephalomyelitis (EAE), it exacerbates NMOSD-like astrocytopathy. Deleting IFNAR1 counteracts this effect by selectively enhancing astrocyte activation without altering other CNS cells. Subsequently, we characterized multiple MS therapeutics that paradoxically worsen NMOSD-like pathology, whereas agents promoting astrocytic activation confer protection. Collectively, we establish a framework for astrocyte-centered drug screening and underscore the therapeutic potential of targeting astrocytes in NMOSD, connecting fundamental disease mechanisms to clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Medicinal Resources and Natural Pharmaceutical Chemistry, Ministry of Education, College of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.
- Key Laboratory for Medicinal Resources and Natural Pharmaceutical Chemistry, Ministry of Education, College of Life Sciences, Shaanxi Normal University, Xi'an 710119, China. Electronic address: zy114l@snnu.edu.cn.
- Key Laboratory for Medicinal Resources and Natural Pharmaceutical Chemistry, Ministry of Education, College of Life Sciences, Shaanxi Normal University, Xi'an 710119, China. Electronic address: yaping.yan@snnu.edu.cn.
Förderung
- Shaanxi Province Natural Science Foundation
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Dai, L., Cheng, G., Cui, T., He, S., Wang, R., Kang, J., Li, P., Zhang, X., Ding, X., Xue, X., Yang, L., Zhang, Y., & Yan, Y. (2026). Activation status of astrocytes drives the MS/NMOSD therapeutic paradox: Insights from IFNAR1 signaling. Cell Reports, 45(2), 116913. https://doi.org/10.1016/j.celrep.2025.116913
Vancouver
Dai L, Cheng G, Cui T, He S, Wang R, Kang J, et al. Activation status of astrocytes drives the MS/NMOSD therapeutic paradox: Insights from IFNAR1 signaling. Cell Reports. 2026;45(2):116913. doi:10.1016/j.celrep.2025.116913
BibTeX
@article{Dai2026,
author = {Dai, Luhang and Cheng, Guo and Cui, Tingting and He, Sitong and Wang, Ran and Kang, Jingqi and Li, Pei and Zhang, Xin and Ding, Xiaoli and Xue, Xiaochang and Yang, Luting and Zhang, Yaling and Yan, Yaping},
title = {Activation status of astrocytes drives the MS/NMOSD therapeutic paradox: Insights from IFNAR1 signaling},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {2},
pages = {116913},
doi = {10.1016/j.celrep.2025.116913}
}
EUVIMED